Government tenders for production of life-saving drugs in Russia

8 July 2011

The Russian Ministry of Industry and Trade Ministry has announced a tender for the production of five imported drugs, which are not produced by domestic manufacturers, and are not protected by patents of foreign companies in Russia.

Among these drugs are gadodiamide and iohexol (both diagnostic contrast media agents), propofol, a drug that reduces anxiety and tension, and promotes relaxation and sleep or loss of consciousness, as well as ropivacaine, and sevoflurane, which are used for anesthesia. All of the drugs are considered as life-saving.

Under the terms of the tender, the government plans to allocate 18 million rubles (around $650,000) for the development of technology and organization of production per each lot. Tenders are expected to be held on August 3.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Generics